Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2014

View Archived Issues

Phase I results presented for the new PET tracer [18F]-FSPG

Foamix begins phase II trial of FDX-104 to prevent EGFR inhibitor-induced rash

Merck Serono, the ICR and the Wellcome Trust collaborate to discover tankyrase inhibitors

NanoString Technologies and Brigham and Women's Hospital collaborate to develop cancer diagnostics

MicroRNA identified as a biomarker target for MS

Interim phase II results for squalamine lactate plus ranibizumab in neovascular AMD

SNP signature linked to response to glatiramer in patients with MS

AbbVie discloses novel CDK9/cyclin-T1 inhibitors for cancer

BNN-93, a novel neuroprotective ocular solution

Researchers at Oncodesign patent novel RIP-2 inhibitors

Sanofi divulges new SGK1 inhibitors

Researchers in London prepare novel SSAO inhibitors for COPD and other disorders

A team of scientists at Novartis synthesize new complement C5 convertase inhibitors

FDA grants orphan drug status to DNX-2401 for glioma

MacroGenics begins phase I study of MGD-007

FDA grants fast track designation to NurOwn for ALS

DiscoveryBioMed receives grant for ADPKD drug development

StemCells begins phase II trial of HuCNS-SC in cervical SCI

NIAID awards grant to Hampton University for work in infectious disease

Bristol-Myers Squibb withdraws NDA for asunaprevir

Generex Biotechnology explores opportunities for Antigen Express technology against Ebola

Orphazyme prepares phase II/III trial of arimoclomol in Niemann-Pick disease type C

Lead Discovery Center and UiT The Arctic University of Norway seek drugs in arctic sea organisms

Second Genome partners with Mayo Clinic to develop microbiome therapeutics

Cardio3 BioSciences gains preferred access to Mayo Clinic technologies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...